An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced participation in the Chardan Virtual 5th Annual Genetic Medicines Conference. CEO Gaurav Shah will join a fireside chat on October 5, 2021, at 10:30 am ET, while CMO Jonathan Schwartz will discuss genetic medicines on a panel on October 4, 2021, at 3:00 pm ET. The event's webcast will be available on Rocket's website, with an archive accessible for 30 days.
Rocket focuses on genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon disease.
Positive
None.
Negative
None.
CRANBURY, N.J.--(BUSINESS WIRE)--
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announced that Gaurav Shah, M.D., chief executive officer, will participate in a fireside chat on Tuesday, October 5, 2021, at 10:30 am ET at the Chardan Virtual 5th Annual Genetic Medicines Conference. In addition, Jonathan Schwartz, M.D., chief medical officer, will be part of a panel discussion: “Genetic Medicines: The Ongoing Emergence of the Heart as a Target Tissue” on Monday, October 4, at 3:00 pm ET.
The live webcast of the fireside chat will be accessible via Rocket’s website on the Events page. An archived copy of the webcast will be available on the Rocket website for 30 days after the event.
About Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.
When will Rocket Pharmaceuticals participate in the Genetic Medicines Conference?
Rocket Pharmaceuticals will participate in the Chardan Virtual 5th Annual Genetic Medicines Conference on October 5, 2021.
What time is the fireside chat featuring Rocket's CEO?
The fireside chat featuring CEO Gaurav Shah will take place at 10:30 am ET on October 5, 2021.
Who will represent Rocket Pharmaceuticals on the panel discussion?
CMO Jonathan Schwartz will represent Rocket Pharmaceuticals during the panel discussion on October 4, 2021 at 3:00 pm ET.
How can I access the webcast of Rocket Pharmaceuticals' conference participation?
The live webcast can be accessed via the Events page on Rocket Pharmaceuticals' website, with an archived version available for 30 days post-event.
What types of therapies does Rocket Pharmaceuticals focus on?
Rocket Pharmaceuticals focuses on genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon disease, utilizing both lentiviral and adeno-associated virus-based therapies.
